Skip to main content
OpenTrials

Clinical trial condition

Advanced Solid Tumors

Explore clinical trials studying Advanced Solid Tumors. Study availability and eligibility vary by location and protocol.

609 public trials 183 recruiting studies
Refine in advanced search Browse all conditions

Advanced Solid Tumors trial results

Completed

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

NCT03000257

Conditions
Adenocarcinoma, Adenoma, Adnexal Diseases, +56 more
Locations
  • Moores Cancer Center at UC San Diego /ID# 157374 La Jolla, California, United States
  • The University of Chicago Medical Center /ID# 157375 Chicago, Illinois, United States
  • Carolina BioOncology Institute /ID# 157376 Huntersville, North Carolina, United States
  • South Texas Accelerated Research Therapeutics /ID# 157378 San Antonio, Texas, United States
View all 26 locations
View Trial Details
Completed

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumors, +47 more
Locations
  • Scottsdale Healthcare Hospitals DBA Honor Health Scottsdale, Arizona, United States
  • Moores UC San Diego Cancer Center La Jolla, California, United States
  • Norris Comprehensive Cancer Center, University of Southern California Los Angeles, California, United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Center Los Angeles, California, United States
View all 39 locations
View Trial Details
Completed

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

NCT02442414

Conditions
Advanced Solid Tumors, Bronchial Neoplasms, Carcinoma, Bronchogenic, +19 more
Locations
  • Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • University of Utah Huntsman Cancer Institute Salt Lake City, Utah, United States
View Trial Details
Completed

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02460224

Conditions
Adenoma, Advanced Solid Tumors, Bronchial Neoplasms, +31 more
Locations
  • Columbia University Medical Center SC LAG X2101C New York, United States
  • Memorial Sloan Kettering Cancer Center SC New York, United States
  • Duke Clinical Research Institute SC Durham, North Carolina, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 24 locations
View Trial Details

Related conditions